- Walgreens allies with HHS to launch free flu shot outreach to disadvantaged
- Pfizer forms licensing agreement with Seattle Genetics
- FDA approves Merck's Gardasil for prevention of anal cancer
- FDA approves Novartis drug for high blood pressure treatment
- Walgreens puts its money where its mouth is with World AIDS Day campaign
NEW YORK — The Food and Drug Administration has approved a Pfizer vaccine for Streptococcus pneumoniae in adults ages 50 years and older, the company said.
Pfizer announced the FDA approval of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) as a single-dose for adults.
"Pneumococcal disease, including pneumonia, in adults 50 years and older represents a significant personal and social health burden in the United States," Pfizer chairman and CEO Ian Read said. "The FDA approval of Prevnar 13 for these adults offers the potential to contribute to the health of millions of aging Americans."